Dendreon Corp fka DNDNQ

[walldiver]

No matter what anyone hears from IR, it's entirely possible that when the company announced enrollment was completed in June 05, it actually meant "enrollment" and not randomization. Remember that every patient in the trial underwent Lupron treatment until his PSA score dropped far enough for him to be randomized.

This would be one of the two possible scenarios where things wouldn't be so positive for Provenge in P-11 despite the length of time that has passed, the other scenario being an unexpectedly good benefit in the Lupron-only arm.